Drugs / TdaP booster
TdaP booster
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02382913 | Apr → Jun 2015 | pertussis | Novartis | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TdaP booster | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02382913 ↗ |
| Known as | Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) | “Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different...” NCT02382913 ↗ |
| Modality | Vaccine | “Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed)” NCT02382913 ↗ |
| Route | Intramuscular | “Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly” NCT02382913 ↗ |